SciSparc Ltd. Ordinary Shares
SPRCSciSparc Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company specializes in leveraging proprietary formulations of cannabinoids and other compounds to address conditions such as schizophrenia, autism spectrum disorder, and other neurological and psychiatric conditions. SciSparc aims to advance innovative therapies through research and clinical trials to improve patient outcomes in CNS health.
Company News
SciSparc Ltd. (NASDAQ: SPRC) stock surged 157% on Thursday following a pre-market announcement that its majority-owned subsidiary NeuroThera Labs Inc. received conditional regulatory approval from the TSX Venture Exchange. The approval clears the path for NeuroThera to acquire a 54% majority stake in CliniQuantum Ltd., an Israeli technology compa...
SciSparc's majority-owned subsidiary NeuroThera Labs has signed a definitive agreement to acquire approximately 54% of CliniQuantum, a quantum technology company specializing in quantum-based clinical trials. NeuroThera will issue 56.6 million common shares valued at approximately $9.46 million, with potential earn-out payments up to $2.5 million...
SciSparc's subsidiary NeuroThera Labs has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data analysis company, aiming to leverage quantum computing principles for more efficient clinical data processing and research.
SciSparc Ltd. has entered into an agreement to acquire a controlling interest in Miza III Ventures Inc., transferring its advanced clinical stage pharmaceutical portfolio and equity stake in SciSparc Nutraceuticals Inc. The transaction values the target assets at approximately $11.6 million and is expected to close around October 22, 2025.
Multiple health care stocks experienced significant price movements during Monday's after-market trading session, with some companies seeing notable gains while others experienced declines.
